Stifel upgraded Oxford Biomedica to Buy from Hold with a price target of 300 GBp, up from 280 GBp. The analyst says the company offers exposures to the “rapidly growing” cell and gene therapy space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
